ArticleCureus2026
Adipokine Profile in Non-alcoholic Fatty Liver Disease.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Body roundness index and adolescent metabolic syndrome: dose-response analysis and serum biomarker mediation.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-alcoholic fatty liver disease (NAFLD) is commonly linked with metabolic disturbances such as central obesity, insulin resistance, dyslipidaemia and low-grade inflammation. Adipokines released from adipose tissue may influence hepatic fat accumulation, metabolic dysfunction and progression of liver injury. This study was conducted to assess the serum adipokine profile in patients with NAFLD, compare it with healthy controls and evaluate its relationship with anthropometric and biochemical parameters. MATERIALS AND
methodsThis case-control study included 100 participants, consisting of 50 patients with ultrasound-diagnosed NAFLD and 50 age- and sex-matched healthy controls. Demographic details, body mass index, waist circumference, fasting blood glucose, fasting insulin, lipid profile and liver function parameters were recorded. Serum adiponectin, leptin, resistin and visfatin levels were measured using enzyme-linked immunosorbent assay. Insulin resistance was assessed using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) index. The data were analysed to compare adipokine levels between the two groups and to determine their association with metabolic variables.
resultsThe mean age of patients with NAFLD was 43.8 ± 9.6 years. Among them, 29 patients (58.0%) were males and 21 patients (42.0%) were females. Compared with controls, patients with NAFLD had significantly higher body mass index (29.1 ± 3.8 vs 23.7 ± 2.9 kg/m²), waist circumference (96.4 ± 8.7 vs 82.6 ± 7.9 cm), fasting blood glucose (112.8 ± 18.5 vs 91.6 ± 10.7 mg/dL), triglycerides (186.5 ± 42.3 vs 124.7 ± 31.8 mg/dL) and HOMA-IR (3.8 ± 1.2 vs 1.7 ± 0.6), with p < 0.001 for all comparisons. Serum adiponectin was significantly lower in the NAFLD group than in controls (5.9 ± 2.1 vs 10.8 ± 3.4 µg/mL; p < 0.001). In contrast, serum leptin (24.6 ± 8.9 vs 12.3 ± 5.4 ng/mL), resistin (14.8 ± 4.6 vs 8.7 ± 3.1 ng/mL) and visfatin (32.5 ± 10.2 vs 18.9 ± 7.6 ng/mL) were significantly higher among patients with NAFLD (p < 0.001). Adiponectin showed a negative correlation with body mass index, triglycerides and HOMA-IR, whereas leptin and resistin showed positive correlations with these parameters.
conclusionPatients with NAFLD showed a clear adipokine imbalance, characterised by reduced adiponectin and increased leptin, resistin and visfatin levels. This pattern was associated with obesity, dyslipidaemia and insulin resistance, indicating that adipokine alterations may contribute to the metabolic and inflammatory mechanisms involved in NAFLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.